RxSight, Inc.
Financials
Valuation Metrics
RxSight, Inc.'s Market Cap is $198M. At end of 2025 it was $429M. Ranked #2978 of 3,116 in US market (top 96%), #1362 of 1,472 on NASDAQ (top 93%), #189 of 203 in Health Care Equipment & Services (top 93%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $198M | US#2,978/3,116 Sec#189/203 |
| Revenue | $128M | US#2,629/3,116 Sec#177/203 |
| Net Income | $-47M | US—/3,116 Sec—/203 |
| Total Assets | $353M | US#2,871/3,116 Sec#170/203 |
| Net Assets | $263M | US#2,565/3,116 Sec#150/203 |
| Employees | 461 | US#2,293/3,116 Sec#158/203 |
| Value | ||
| P/B | 0.75x | US#239/3,116 Sec#10/203 |
| P/S | 1.56x | US#1,104/3,116 Sec#71/203 |
| FCF Yield | -13.69% | US—/3,116 Sec—/203 |
| Profitability | ||
| ROE | -17.83% | US#2,457/3,116 Sec#150/203 |
| ROA | -13.31% | US#2,708/3,116 Sec#160/203 |
| Op. Margin | -43.20% | US#2,641/3,116 Sec#178/203 |
| Revenue Growth | -18.82% | US#2,631/3,116 Sec#195/203 |
| Financial Health | ||
| Debt Ratio | 33.93% | US#385/3,116 Sec#39/203 |
| Total Debt | $11M | US#2,819/3,116 Sec#186/203 |
| FCF | $-27M | US#2,453/3,116 Sec#167/203 |
| Cash | $13M | US#2,918/3,116 Sec#194/203 |
| Current Ratio | 4.07x | US#559/3,116 Sec#54/203 |
| Performance | ||
| 1Y Return | -45.45% | US#2,760/3,116 Sec#178/203 |
| 1M Return | 2.46% | US#1,170/3,116 Sec#116/203 |
| From 52W High | -63.73% | US#2,894/3,116 Sec#193/203 |
| 1Y MDD | -65.55% | US#2,857/3,116 Sec#184/203 |
| Trading | ||
| Volume | 643,597 shares | US#1,644/3,116 Sec#109/203 |
| Trading Value | $3M | US#2,696/3,116 Sec#175/203 |
| Per Share | ||
| EPS | $-1.13 | US—/3,116 Sec—/203 |
| BPS | $6.36 | US#2,149/3,116 Sec#133/203 |
Company Info
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.